Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2017 / Cilt: 30 - Sayı: 1

Pregabalin Addiction in a Case with Synthetic Cannabinoid Use

Sentetik kannabinoid kullanımı olan bir olguda pregabalin bağımlılığı

Pages
62–65
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures.
📊
Key Findings & Data:Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels.
💡
Conclusion & Impact:This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse

Özet

Sentetik kannabinoid kullanımı olan bir olguda pregabalin bağımlılığıPregabalin nöropatik ağrı ve parsiyel nöbetlerin tedavisi için onaylanmış bir gama-aminobutirik asit (GABA) analogudur. Pregabalin seçici voltaja duyarlı kalsiyum kanallarının alfa 2 delta alt ünitesine bağlanır. Böylece eksitatör nöro-transmitter salınımını inhibe ederken nöronal GABA düzeylerini artırır. Pregabalinin aynı zamanda Yaygın Anksiyete Bozukluğu'nun tedavisinde kullanımı Avrupa İlaç Komisyonu tarafından onaylanmıştır. Pregabalinin anksiyolitik etkisi benzodiazepinlerin etkisine benzer ve uygulamadan sonra hızla ortaya çıkar. Ancak, Amerika Gıda ve İlaç Dairesi (FDA) ile Avrupa Tıbbi Ürünler Ajansı (EMA) tarafından "Kontrollü Kullanılması Gereken Maddeler V" listesine alınmıştır. Bu, pregabalinin benzodiazepinler gibi kötüye kullanılma potansiyeli düşük olan ilaçlar arasında kabul edildiği anlamına gelmektedir

🔖

Cite This Article

KÖROĞLU, G. (2017). Pregabalin Addiction in a Case with Synthetic Cannabinoid Use. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 30 - Sayı: 1, 62–65. https://ajindex.com/articles/218474

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. https://www.drugs.com/schedule-5-drugs.html. Accessed February 28, 2017
  2. Stahl SM. Stahl’s Essential Psychopharmacology. Tunc Alkin (Translation Editor) Fourth ed., Istanbul: Istanbul Tip Kitabevi, 2015; 71-72. (Turkish
  3. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110:628-638. [CrossRef] 4. Jensen TS. Finnerup NB. Management of neuropathic pain. Curr Opin Support Palliat Care 2007; 1:126-131. [CrossRef] 5. Derry S, Cording M, Wiffen PJ, S Law, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. http://onlinelibrary. wiley.com/doi/10.1002/14651858.CD011790.pub2/full. Accessed February 28, 2017
  4. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014; 5:38-56. [CrossRef] 7. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62:1022- 1030. [CrossRef] 8. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014; 28:835-854. [CrossRef] 9. Center for Drug Evaluation and research, U.S. Food and Drug Administration Medical Review (internet) In: Lyrica (pregabalin) capsules. Company: Pfizer, Inc. Aplication No:21-446. https:// www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf. Accessed February 28, 2017
  5. European Medicines Agency. http://www.ema.europa.eu/docs/ en_GB/document. Accessed February 28, 2017
  6. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010; 167:869. [CrossRef] 12. Filipetto FA, Zipp CP, Coren J. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 2010; 110:605-607
  7. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations and possible association with myositis: two case reports. J Clin Psychopharmacol 2012; 32:839-840. [CrossRef] 14. Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report. Bulletin of Clinical Psychopharmacology 2011; 21:64-66. [CrossRef] 15. Aldemir E, Altintoprak AE, Coskunol H. Pregabalin dependence: a c